Selected research
Industry Research
Rare Genetic Disease Diagnosis Solution Industry Research Report 2026
Market perspective
The global Rare Genetic Disease Diagnosis Solution market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Rare Genetic Disease Diagnosis Solution market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Rare Genetic Disease Diagnosis Solution market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Rare Genetic Disease Diagnosis Solution market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Rare Genetic Disease Diagnosis Solution include Retrophin, 3billion, 23andMe, Ancestry, GeneDx, Ambry Genetics, QIAGEN, Illumina and PerkinElmer and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Rare Genetic Disease Diagnosis Solution market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Rare Genetic Disease Diagnosis Solution.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rare Genetic Disease Diagnosis Solution Market by Company
Retrophin
3billion
23andMe
Ancestry
GeneDx
Ambry Genetics
QIAGEN
Illumina
PerkinElmer
Strand Life Sciences
Rare Genetic Disease Diagnosis Solution Segment by Type
Genetic Testing
Biochemical Testing
Imaging and Diagnostic Procedures
Others
Rare Genetic Disease Diagnosis Solution Segment by Application
Clinical Genetics and Pediatric Clinic
Newborn Screening Program
Research and Development
Others
Rare Genetic Disease Diagnosis Solution Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Genetic Disease Diagnosis Solution market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Genetic Disease Diagnosis Solution and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Genetic Disease Diagnosis Solution.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Rare Genetic Disease Diagnosis Solution companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Genetic Testing
- Biochemical Testing
- Imaging and Diagnostic Procedures
- Others
Applications
- Clinical Genetics and Pediatric Clinic
- Newborn Screening Program
- Research and Development
- Others
Companies covered
- Retrophin
- 3billion
- 23andMe
- Ancestry
- GeneDx
- Ambry Genetics
- QIAGEN
- Illumina
- PerkinElmer
- Strand Life Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Rare Genetic Disease Diagnosis Solution by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Genetic Testing
- 2.2.3 Biochemical Testing
- 2.2.4 Imaging and Diagnostic Procedures
- 2.2.5 Others
- 2.3 Rare Genetic Disease Diagnosis Solution by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinical Genetics and Pediatric Clinic
- 2.3.3 Newborn Screening Program
- 2.3.4 Research and Development
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Rare Genetic Disease Diagnosis Solution Breakdown Data by Type
- 3.1 Global Rare Genetic Disease Diagnosis Solution Historic Market Size by Type (2021-2026)
- 3.2 Global Rare Genetic Disease Diagnosis Solution Forecasted Market Size by Type (2027-2032)
4 Rare Genetic Disease Diagnosis Solution Breakdown Data by Application
- 4.1 Global Rare Genetic Disease Diagnosis Solution Historic Market Size by Application (2021-2026)
- 4.2 Global Rare Genetic Disease Diagnosis Solution Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Rare Genetic Disease Diagnosis Solution Market Perspective (2021-2032)
- 5.2 Global Rare Genetic Disease Diagnosis Solution Growth Trends by Region
- 5.2.1 Global Rare Genetic Disease Diagnosis Solution Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Rare Genetic Disease Diagnosis Solution Historic Market Size by Region (2021-2026)
- 5.2.3 Rare Genetic Disease Diagnosis Solution Forecasted Market Size by Region (2027-2032)
- 5.3 Rare Genetic Disease Diagnosis Solution Market Dynamics
- 5.3.1 Rare Genetic Disease Diagnosis Solution Industry Trends
- 5.3.2 Rare Genetic Disease Diagnosis Solution Market Drivers
- 5.3.3 Rare Genetic Disease Diagnosis Solution Market Challenges
- 5.3.4 Rare Genetic Disease Diagnosis Solution Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Rare Genetic Disease Diagnosis Solution Players by Revenue
- 6.1.1 Global Top Rare Genetic Disease Diagnosis Solution Players by Revenue (2021-2026)
- 6.1.2 Global Rare Genetic Disease Diagnosis Solution Revenue Market Share by Players (2021-2026)
- 6.2 Global Rare Genetic Disease Diagnosis Solution Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Rare Genetic Disease Diagnosis Solution Head Office and Area Served
- 6.4 Global Rare Genetic Disease Diagnosis Solution Players, Product Type & Application
- 6.5 Global Rare Genetic Disease Diagnosis Solution Manufacturers Established Date
- 6.6 Global Rare Genetic Disease Diagnosis Solution Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Rare Genetic Disease Diagnosis Solution Market Size (2021-2032)
- 7.2 North America Rare Genetic Disease Diagnosis Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Rare Genetic Disease Diagnosis Solution Market Size by Country (2021-2026)
- 7.4 North America Rare Genetic Disease Diagnosis Solution Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Rare Genetic Disease Diagnosis Solution Market Size (2021-2032)
- 8.2 Europe Rare Genetic Disease Diagnosis Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Rare Genetic Disease Diagnosis Solution Market Size by Country (2021-2026)
- 8.4 Europe Rare Genetic Disease Diagnosis Solution Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Rare Genetic Disease Diagnosis Solution Market Size (2021-2032)
- 9.2 Asia-Pacific Rare Genetic Disease Diagnosis Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Rare Genetic Disease Diagnosis Solution Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Rare Genetic Disease Diagnosis Solution Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Rare Genetic Disease Diagnosis Solution Market Size (2021-2032)
- 10.2 South America Rare Genetic Disease Diagnosis Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Rare Genetic Disease Diagnosis Solution Market Size by Country (2021-2026)
- 10.4 South America Rare Genetic Disease Diagnosis Solution Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Rare Genetic Disease Diagnosis Solution Market Size (2021-2032)
- 11.2 Middle East & Africa Rare Genetic Disease Diagnosis Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Rare Genetic Disease Diagnosis Solution Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Rare Genetic Disease Diagnosis Solution Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Retrophin
- 12.1.1 Retrophin Company Information
- 12.1.2 Retrophin Business Overview
- 12.1.3 Retrophin Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.1.4 Retrophin Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.1.5 Retrophin Recent Developments
- 12.2 3billion
- 12.2.1 3billion Company Information
- 12.2.2 3billion Business Overview
- 12.2.3 3billion Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.2.4 3billion Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.2.5 3billion Recent Developments
- 12.3 23andMe
- 12.3.1 23andMe Company Information
- 12.3.2 23andMe Business Overview
- 12.3.3 23andMe Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.3.4 23andMe Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.3.5 23andMe Recent Developments
- 12.4 Ancestry
- 12.4.1 Ancestry Company Information
- 12.4.2 Ancestry Business Overview
- 12.4.3 Ancestry Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.4.4 Ancestry Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.4.5 Ancestry Recent Developments
- 12.5 GeneDx
- 12.5.1 GeneDx Company Information
- 12.5.2 GeneDx Business Overview
- 12.5.3 GeneDx Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.5.4 GeneDx Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.5.5 GeneDx Recent Developments
- 12.6 Ambry Genetics
- 12.6.1 Ambry Genetics Company Information
- 12.6.2 Ambry Genetics Business Overview
- 12.6.3 Ambry Genetics Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.6.4 Ambry Genetics Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.6.5 Ambry Genetics Recent Developments
- 12.7 QIAGEN
- 12.7.1 QIAGEN Company Information
- 12.7.2 QIAGEN Business Overview
- 12.7.3 QIAGEN Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.7.4 QIAGEN Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.7.5 QIAGEN Recent Developments
- 12.8 Illumina
- 12.8.1 Illumina Company Information
- 12.8.2 Illumina Business Overview
- 12.8.3 Illumina Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.8.4 Illumina Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.8.5 Illumina Recent Developments
- 12.9 PerkinElmer
- 12.9.1 PerkinElmer Company Information
- 12.9.2 PerkinElmer Business Overview
- 12.9.3 PerkinElmer Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.9.4 PerkinElmer Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.9.5 PerkinElmer Recent Developments
- 12.10 Strand Life Sciences
- 12.10.1 Strand Life Sciences Company Information
- 12.10.2 Strand Life Sciences Business Overview
- 12.10.3 Strand Life Sciences Revenue in Rare Genetic Disease Diagnosis Solution Business (2021-2026)
- 12.10.4 Strand Life Sciences Rare Genetic Disease Diagnosis Solution Product Portfolio
- 12.10.5 Strand Life Sciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst